Table 2 Shows the results of the analysis of the secondary outcomes

The additional use of uterotonic agents

OR = 0.46, 95%CI [0.34 to 0.62], P = 0.01; (I² = 52.53%)

[24, 25, 29, 33, 37, 38, 41, 48, 53, 54, 60,61,62, 65]

OR = 0.55, 95%CI [0.37 to 0.80], P = 0.02; (I² = 45.62%)

[18, 27, 30, 36, 42, 46, 50, 58, 66, 76, 77]

Postoperative blood loss

MD= -1.54 mL, 95%CI [-2.02 to -1.06], P = 0.01; (I² = 67.76%)

[12, 24, 26, 28, 33, 34, 38, 39, 44, 45, 49, 51,52,53, 56, 57, 59, 62,63,64, 67, 70,71,72, 75]

MD= -0.55 mL, 95%CI [-0.73 to -0.37], P = 0.01; (I² = 20.91%)

[36, 50, 78]

Intra-operative blood loss

MD= -1.96 mL, 95%CI [-2.77 to -1.15], P < 0.001; (I² = 69.15%)

[12, 24, 26, 28, 33,34,35, 38, 39, 44, 45, 49, 51,52,53, 56, 57, 62,63,64, 67, 70,71,72, 75]

MD = 0.05 mL, 95%CI [-0.21 to 0.31], P = 0.70; (I² = 33.51%)

[30, 50]

The incidence of hysterectomy

OR = 1.59, 95%CI [0.71 to 3.53], P = 0.26; (I² = 0.00%)

[25, 37, 53, 54, 60, 64, 69]

OR = 0.34, 95%CI [0.07 to 1.75], P = 0.20; (I² = 0%)

[27, 30, 78]

Occurrence of nausea/vomiting

OR = 1.36, 95%CI [1.07 to 1.74], P = 0.01; (I² = 12.63%)

[12, 31, 32, 35, 38, 43, 52,53,54, 57, 60, 69,70,71]

OR = 2.36, 95%CI [1.32 to 4.21], P = 0.02; (I² = 67.19%)

[27, 30, 36, 50, 66, 74, 77, 78]